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Abstract We have demonstrated that the 50 N-terminal amino 
acids of c-Myc bind a kinase activity, which phosphorylates Myc 
in vitro predominantly on Thr 8. We also have shown that c-Raf, a 
widely known Ser/Thr kinase, involved in the Ras signaling 
pathway, binds to the same portion of c-Myc in vitro. In addition 
we were able to precipitate native c-Myc/Raf complex from 
various cell lysates. Physical interaction of Myc and Raf may 
potentially be a part of their well-known functional cooperation. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
This work is a part of an ongoing effort to identify the 
proteins interacting with an oncoprotein c-Myc, which is a 
nuclear phosphoprotein acting as a transcription factor that 
was shown to play an important functional role in cell pro- 
liferation, differentiation, neoplasia and apoptosis [1 3]. c- 
Myc contains two major functional domains each of which 
interacts with several binding factors that can modulate Myc 
functional activity. The C-terminal domain interacts with 
Max, through its leucin-zipper and helix loop-helix domains. 
Max/Myc heterodimers are required for modulating transcrip- 
tional activity of Myc [3]. The N-terminal domain of c-Myc 
both a transactivation and transformation domain and inter- 
acts with several proteins such as the retinoblastoma-related 
protein p107 [4], the transcriptional regulators Yin-Yang 
(YY-I) [5] and AP-2 [6], the TATA-binding protein (TBP) 
[7], TFI I - I  [8]. In addition, MAP kinase has been shown to 
bind and phosphorylates c-Myc in this region [9]. In our pre- 
vious work, we showed, that c-Myc N-terminal region is able 
to bind to tubulin and to microtubules [10]. 
c-Raf is a Ser/Thr kinase which participates in an evolu- 
tionarily conserved cascade transducing signals from plasma 
membrane to the nucleus (reviewed in [11]). It plays a critical 
role in cell growth and differentiation and can cooperate in a 
cotransformation assay with c- and v-Myc. Raf  induces the 
expression of immediate early genes (los and myc among 
them). Its activity is regulated by multiple protein~rotein 
interactions and phosphorylation events. Ras activates Raf, 
binding to it directly and recruiting it to the plasma mem- 
brane. Activated Raf  is often associated with cytoskeletal el- 
ements [12]. c-Raf can phosphorylate and activate MAP kin- 
ase kinase that in turn activates MAP kinase, which is known 
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to bind and phosphorylate c-Myc [t3,14]. In addition, Raf 
associates with a large number of proteins, which may mod- 
ulate its activity (e.g. 14-3-3 protein) or contribute to target 
recognition (e.g. MEK and c-jun). 
Our data show that Raf  binds to amino terminal end of c- 
Myc protein suggesting that physical interaction of the prod- 
ucts of these two oncogenes may underlie their biological 
cooperation. 
2. Materials and methods 
2.1. Materials 
[¥-:I~P]ATP was purchased from Amersham, USA. Thrombin was 
purchased from Sigma. Raf monoclonal antibodies were purchased 
from Transduction Laboratories Inc. Monoclonal c-Myc antibodies 
lAb-l) were purchased from Oncogene Science. Recombinant GST 
fusion proteins were prepared by bacterial expression and glutathione 
agarose beads (Pharmacia) affinity chromalography asdescribed [15]. 
Ultra pure myelin basic protein (MBP) was purchased from UB1. 
2.2. Tissue cultures 
CEM (T-lymphoid) and HL60 (myeloid leukemia) human cell lines 
were maintained in RPMI-1640 medium with 10% fetal call" serum 
(Gibco-BRL). All main experiments were performed using the lysates 
of each of these three cell lines and identical results were obtained. 
2.3. Expression of GST-Myc jusion proteins 
Construction of pGEX-based plasmids (Pharmacia), containing 
GST Myc fusion proteins, bearing a unique thrombin cleavage site 
between Myc and GST moieties, have been described [10]. 
2.4. Binding assays 
Cells were lysed in EBC binding buffer (1 mM EDTA, 0.5'!,/,, Non- 
idet P-40, 120 mM NaCI, 10 gg/ml leupeptin, 1 mM PMSF, 50 mM 
Tris-HC1, pH 8.0, 1 mM NaF, 0.2 mM orthovanadate and 1 mM 
DTT), kept 20 min at 0°C and then centrifuged in a microfuge for 
30 min at 4°C. Cell extract (200 lal, containing 100, gg of total protein) 
was incubated with GST fusion proteins prebound to 20 btl of gluta- 
thione-agarose b ads as described [10]. After 60 min of incubation at 
4°C the agarose beads were washed 5 times. The bound proteins were 
separated on SDS-PAGE. 
2.5. In vitro protein kinase assays with proteins hound to GST heads 
GST beads with immobilized fusion proteins were incubated with 
cell lysates and washed as above, then equilibrated with kinase buffer, 
containing 10 mM MgC12, 10 mM HEPES, pH 7.0. Kinase assays 
were performed in 50 gl of kinase buffer with 1 btCi [¥-a~P]ATP. The 
phosphorylation reactions were performed for 20 min at room tem- 
perature and terminated by washing the beads 3 times with EBC, and 
subsequent addition of Laemmli sample buffer. The phosphorylated 
proteins were resolved by SDS-PAGE and visualized by autoradiog- 
raphy. 
2.6. Phosphoamino acid analysis 
Phosphoamino acid analysis was performed as described earlier [16] 
with slight modifications. Fusion protein on beads was phospho- 
rylated in vitro with CEM cell lysate as a source of kinase activity 
as described above, and cleaved with thrombin according to the pro- 
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Fig. 1. Kinase activity binds to N-terminal part of c-Myc. A: Mycl-50 fusion protein or GST alone as a control were immobilized on the glu- 
tathione beads and incubated with CEM cell lysate. Kinase assay was performed in the presence of MgC12 and ['p32p]ATP. The phosphorylated 
proteins were examined by SDS-PAGE and subsequent autoradiography. B: Kinase assay was performed as above with an addition of 4 gg of 
purified MBP as an exogenous phosphorylation substrate. 
cedure described in [17]. The cleaved product was purified on 
SDS-PAGE, eluted from the gel by incubation in 1% SDS at 67°C 
and acetone precipitated. Then it was resuspended [n 6 N HC1 
(Pierce), hydrolysed for 4 h at 105°C, the acid was evaporated, 
hydrolysates were mixed with markers and electrophoresed on 
thin-layer cellulose plate (J.T. Baker) at 1100 V in 5% acetic acid, 
0.5% pyridine. Markers were visualized by staining with ninhydrin 
solution (Sigma) and labeled phosphoamino acids by autoradiog- 
raphy. 
2. 7. Western blot analysis 
After SDS-PAGE the separated proteins were transferred to Nitro- 
cellulose membrane (Schleicher & Schull) and analyzed by Western 
blotting. The membrane were probed with monoclonal Ab-I Myc 
antibodies or monoclonal Raf antibodies. Immune complexes were 
visualized using ECL procedure (Amersham) according to manufac- 
turer's recommendations. 
2.8. Immunoprecipitation 
CEM cell lysate (1 mg/ml of total protein) prepared in EBC buffer 
with either NP-40 or Brij-96 was precipitated with c-Myc, c-Raf or 
unrelated antibodies, using agarose G beads (Oncogene Science) as 
recommended by manufacturer. Precipitated proteins were resolved 
by SDS-PAGE, transferred to the nitrocellulose filters and immuno- 
blotted with c-Myc antibodies. Identical results were obtained with 
NP-40 and Brij lysates. 
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Fig. 2. M ycl-5t) is phosphorylated by Mg2~/Mn: ~-dependent Shr/Thr kinase. A: In vitro phosphorylated GSTMycl-50 fusion protein was sub- 
jected to partial thrombin digestion, which cleaves off 1 50 peptide. Thrombin cleavage ~as done as in [11]. Electrophoresis was performed in 
SDS 8 20% gradient gel (BioRad). Mycl-50 peptide was excised and eluted from the gel and subjected to phosphoamino acid analysis. B: The 
purified peptide was hydrolyzed at I I0°C in 6 N HC1. Hydrolysate was mixed with markers and phosphoamino acids were separated by elec- 
trophoresis on thin layer cellulose plates. Markers were visualized by ninhydrin staining and :~eP-labeled phosphoamino acids by autoradiogra- 
phy. C: In vitro kinase assay was performed in the buffer containing 10 mM HEPES, pH 7.0, and either of the following salts: 10 mM CaCle, 
MgCle or MnCI2. 
3. Results 
3.1. Protein kinase activi O, associates with N-terminal part (~[ 
c-Mye protein 
Different parts of c-Myc N-terminal exon II (amino acids 
1 252) were expressed separately as glutathione-S-transferase 
(GST) fusion proteins and were designated as GSTMycl-50, 
GSTMycl-  134, GSTMyc49-252, GSTMyc102-252 and 
GSTMyclI ,  respectively ([10], see also Fig. 3B). Binding of 
protein kinases was investigated by incubation of c-Myc/ 
GST proteins immobilized on the glutathione agarose beads 
with cell extracts prepared from cultured cells. After extensive 
washing the bound protein kinases were detected by addition 
of [y-:~2P]ATP in kinase buffer. As it is shown on Fig. IA 
GSTMycl-50, containing only the first 50 amino acids of c- 
Myc, was significantly phosphorylated in in vitro kinase assay, 
while GST was not phosphorylated. We surveyed the known 
sites of phosphorylation i the c-Myc molecule in order to 
find a candidate kinase, but none in this region were previ- 
ously reported. 
c-Myc protein is phosphorylated by casein kinase II at two 
different regions between residues 240 262 and 342--357 [18]. 
MAP kinase is able to bind to N-terminal part of c-Myc and 
to phosphorylate it on Thr ~s and Ser ~2 [19]. Few other kinascs 
were shown to phosphorylate the same two amino acids. 
GSTMycl-50 contains neither of the above-mentioned sites 
nor any consensus ites for proline-dependent kinases. Thus, 
phosphorylation of this peptide suggested that another kinase 
may bind to the 1-50 amino acid region. 
Control experiments were performed to show that an un- 
identified kinase indeed binds to the c-Myc peptide, but not to 
the GST sequence. (i) We added an excess of myelin basic 
protein (MBP) as an exogenous substrate in kinase assay. 
Proteins bound to GST produced very little phosphorylation. 
but proteins bound to Myc peptidc strongly phosphorylated 
both MBP and the peptide itself (Fig. IB). This experiment 
has shown that Myc peptide is not merely a substrate to some 
kinase, which binds to GST, but does not phosphorylatc it. 
(ii) In vitro phosphorylated fusion protein was cleaved with 
thrombin right on the border between GST and Myc sequela- 
ces. Myc peptide, but not the GST was phosphorylated (Fig. 
2A). 
Thus, we concluded that the N-terminal amino acids 1.50 
of c-Myc are able to bind some unidentified kinase and con- 
lain in vitro phosphorylation site(st for this kinase. 
3.2. The Mg:+/Mn2+-dependent kinase phosphorvlates c-M.vc 
protein on Thr ~ 
We used the thrombin cleavage product obtained from in 
vitro labeled GSTMycl-50 and purified by SDS-PAGE to 
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Fig. 3. Demonstration f complex formation between c-Myc and c- 
Raf. A,B: We used previously prepared series of MycGST fusion 
proteins with deletions to precipitate proteins from CEM cell ly- 
sates. Bound proteins were separated on SDS-PAGE gel and immu- 
noblotted with c-Raf antibodies. First 50 amino acids of c-Myc are 
sufficient for binding to c-Raf. A: Schematic depiction f fusion 
proteins used. B: Immunoblot with c-Raf antibodies. C: Myc Raf 
complexes were precipitated from CEM cell lysate with either Myc 
or Raf antibodies or unrelated antibodies as a control. Proteins 
were separated on SDS-PAGE and immunoblotted with c-Myc anti- 
bodies. It can be seen that c-Myc is precipitated by Raf and Myc 
antibodies, but not by unrelated antibodies. 
perform phosphoamino acid analysis (Fig. 2B) as previously 
described [16]. Mostly Thr and much smaller amount of Ser 
appeared to be phosphorylated. No phosphotyrosine was ob- 
served. Thr 8 is the only threonine in the Mycl-50 region and 
therefore appeared to be the predominant site of phospho- 
rylation. Consequently, the kinase, bound to N-terminal 
part of c-Myc protein belongs to a Ser/Thr kinase family. 
To further characterize this enzyme, we performed kinase 
assays with different salts: MgCI2, MnC12 and CaCI2 (Fig. 
2C). It appeared that the phosphorylation occurs in the pres- 
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ence of either Mg 2+ or Mn 2+, but not in the presence of Ca 2+. 
This experiment showed, that the kinase is a Mg2+/Mn 2+ 
dependent one. 
3.3. c-Raf kinase is able to bind to N-terminal part of c-Myc 
protein 
In search for potential candidate kinases, we found that c- 
Raf, a Mg2+/Mn 2+ dependent Ser/Thr kinase is able to bind 
to GSTMyc II fusion protein. We used GSTMyc deletion 
mutants in the binding assay (Fig. 3A) to evaluate a number 
and location of binding sites. All fusion proteins were incu- 
bated with HL60 cell lysates and the bound proteins were 
separated by SDS-PAGE and immunoblotted with c-Raf anti- 
bodies. We observed that GSTMycl-50 and GSTMycl-134 
bound to c-Raf, whereas GSTMyc49-252 and GSTMycI02- 
252 failed to bind. These results show that the N-terminal 
amino acids 1-50 of c-Myc are necessary and sufficient for 
Myc/Raf association, and no other binding sites are present 
in the part of c-Myc encoded by exon II. Therefore, c-Raf 
binds to the same N-terminal part of c-Myc protein, as the 
unidentified kinase in our previous experiments. 
Notably, in HL60 cell lysates Raf antibodies reacted with 
two bands, p70 and p74 (Fig. 3A). It was shown previously 
[20] that the two bands represent hypo- (p70) and hyperphos- 
phorylated (p74) forms of Raf. It can be seen that only hypo- 
phosphorylated form binds to c-Myc. 
To find out whether native Myc and Raf proteins form a 
complex, we used co-immunoprecipitation assay: CEM and 
JD38 cell extracts were immunoprecipitated with Raf antibod- 
ies, the precipitate was resolved on SDS-PAGE gel, trans- 
ferred to nitrocellulose filter and immunoblotted with Myc 
antibodies. Isotype matched unrelated antibodies were used 
as a control (Fig. 3C). It appeared that Raf immunoprecipi- 
tate contains c-Myc protein which showed that native Raf and 
Myc proteins may form a complex in vivo. 
4. Discussion 
We describe here the binding of c-Raf to c-Myc. It occurs 
within the N-terminal 50 amino acid region of Myc, which is 
necessary and sufficient for the interaction. Additionally we 
have shown that kinase activity with characteristics identical 
to that of Raf (Ser/Thr kinase, phosphorylating MBP, which 
can use either Mn 2+ or Mg 2+ as the only source of divalent 
cations) binds and phosphorylates this part of c-Myc predom- 
inantly on Thr 8. Whether this activity is indeed c-Raf remains 
to be investigated. 
Although c-Myc is predominantly located in nucleus, while 
Raf is mainly cytoplasmic protein they may be co-localized 
under certain conditions. Activation of Raf kinase in response 
to transmembrane signals may lead to translocation of Raf to 
the nucleus or perinuclear space [21-24]. In HL60 cells a por- 
tion of Myc is localized in the cytoplasm [10]. In quiescent 
cells Myc is mainly cytoplasmic, and only after mitogenic 
stimulation it translocates to the nucleus [25]. Thus, the extent 
of Myc/Raf complex formation may depend on activation 
status of the cells. 
Interestingly, we observed that c-Myc binds preferentially 
to hypophosphorylated form of c-Raf. It is not entirely clear 
how phosphorylation affects c-Raf activity. Although both 
activating and inhibiting phosphorylations may take place 
under different conditions, a general correlation between 
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phosphorylation of Raf and its activation has been observed 
[26]. For instance in quiescent cells Raf is usually hypophos- 
phorylated and has very little, if any, kinase activity [27]. 
Mitogenic stimulation triggers hyperphosphorylation and in- 
duces Raf activity. Thus, our data suggest hat the form of 
Raf which binds c-Myc is predominantly inactive or at least 
less active one. This observation does not favor a possibility 
of direct phosphorylation of c-Myc by Raf. 
The Ser/Thr kinase, which binds to Mycl-50 peptide, de- 
tected in our experiments may represent some background 
kinase activity characteristic of hypophosphorylated form of 
Raf. Alternatively, despite preferential binding of hypophos- 
phorylated tbrm, a much lesser amount of hyperphosphoryl- 
ated, more active Raf may also bind to fusion protein and 
contribute to the kinase activity. On the other hand, it may be 
yet another Ser/Thr kinase binding to c-Myc. 
Importantly, both proteins Raf and Myc are regulated 
by phosphorylation and protein protein interactions, 
which define their activity and compartmentalization. We 
have shown [10] that c-Myc is able to bind to tubulin and 
to microtubules, c-Raf is also known to be associated with 
cytoskeletal elements after recruitment by Ras to the cell 
membrane [12]. 
A number of individual proteins binding c-Myc and c-Raf 
have been discovered. MAP kinase binds and phosphorylates 
Myc in N-terminal region on Thr '~8 and Ser 62. Phosphoryla- 
tion of these amino acids affects properties of Myc as a tran- 
scription factor [18,19]. Also the functionally important inter- 
actions of c-Myc with several proteins, including Max [28,29], 
the pl07-Rb-related protein [4], TFI I - I  [8] and the TATA- 
binding protein [11] have been described. Raf also binds to 
several important proteins. Ras-Raf  binding is the principal 
way of Raf activation [30,31]. Other proteins, interacting with 
Raf are: 14-3-3 protein [32], heat shock protein Hsp90 [33,34], 
PDGF receptor [35] and Bcl-2 [36]. Raf in its phosphorylated 
form binds to T- and 8-chains of CD-3 (the component of T- 
cell receptor) [37]. It was also shown that Raf is able to phos- 
phorylate nuclear oncoproteins such as p53 [38] and jun [39]. 
Phosphorylation of p53 leads to p53-dependent transcription- 
al transactivation. If, as our data suggest, Myc and Raf may 
form complexes in vivo, such binding could be an important 
link in the network of regulatory protein-protein teractions. 
The results of our experiments suggest hat the region con- 
taining first 50 amino acids of c-Myc was sufficient o allow 
binding to c-Raf. The region of Myc to which we have 
mapped Raf phosphorylation is crucial for Myc functioning. 
Amino acids I 143 in c-Myc are required for cotransforma- 
tion with ras in the rat embryo fibroblasts [40]. Amino acids 
1 103 are required for the transcription regulatory activity of 
c-Myc [41]. The same region is crucial for Myc-dependent 
apoptosis [42]. 
It has been known for years that Raf and Myc are func- 
tionally linked: Raf can complement deregulated Myc in tu- 
mor induction in vivo [43], Raf is able to suppress Myc-medi- 
ated apoptosis and thus to cooperate with Myc in abrogation 
of growth factor dependence of tumor cells [44], also Myc and 
Raf cooperate in fibroblast cotransformation assay [45]. Tra- 
ditionally the effect of Raf on Myc function was explained by 
activation of MAP kinase, which phosphorylates Myc. Our 
results allow to suppose that there may be a short-cut in this 
pathway and Rad can influence Myc in a more straightfor- 
ward way through direct or indirect physical interaction. 
Whether this binding has any functional meaning will be a 
subject for further investigation. 
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